CL2012003274A1 - Compuestos derivados de espiro[biciclo[2.2.1]heptano-2,1-(ciclobutano o ciclopentano) y espiro- ([biciclo]oct[5]eno o biciclo[2.2.2]octano)-2,1-ciclopentano, moduladores de receptores nicotinicos; composicion farmaceutica; utiles en el tratamiento de enfermedades o condicion ibs-d, oab, adiccion a la nicotina, depresion, entre otros. - Google Patents

Compuestos derivados de espiro[biciclo[2.2.1]heptano-2,1-(ciclobutano o ciclopentano) y espiro- ([biciclo]oct[5]eno o biciclo[2.2.2]octano)-2,1-ciclopentano, moduladores de receptores nicotinicos; composicion farmaceutica; utiles en el tratamiento de enfermedades o condicion ibs-d, oab, adiccion a la nicotina, depresion, entre otros.

Info

Publication number
CL2012003274A1
CL2012003274A1 CL2012003274A CL2012003274A CL2012003274A1 CL 2012003274 A1 CL2012003274 A1 CL 2012003274A1 CL 2012003274 A CL2012003274 A CL 2012003274A CL 2012003274 A CL2012003274 A CL 2012003274A CL 2012003274 A1 CL2012003274 A1 CL 2012003274A1
Authority
CL
Chile
Prior art keywords
bicyclo
cyclopentane
spiro
treatment
oab
Prior art date
Application number
CL2012003274A
Other languages
English (en)
Inventor
Srinivasa Rao Akireddy
Balwinder Singh Bhatti
Ronald Joseph Heemstra
Matt S Melvin
Jason Speake
Yunde Xiao
Daniel Yohannes
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of CL2012003274A1 publication Critical patent/CL2012003274A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/38—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Compuestos derivados de espirociclos sustituidos, antagonistas no competitivos de receptores nicotínicos neuronales; composición farmacéutica; método de tratamiento o prevención; y su uso para el tratamiento o la prevención de una enfermedad o condición tal como IBS-D, OAB, adicción a la nicotina y dejar de fumar, entre otras.
CL2012003274A 2010-05-27 2012-11-23 Compuestos derivados de espiro[biciclo[2.2.1]heptano-2,1-(ciclobutano o ciclopentano) y espiro- ([biciclo]oct[5]eno o biciclo[2.2.2]octano)-2,1-ciclopentano, moduladores de receptores nicotinicos; composicion farmaceutica; utiles en el tratamiento de enfermedades o condicion ibs-d, oab, adiccion a la nicotina, depresion, entre otros. CL2012003274A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34902710P 2010-05-27 2010-05-27
US37560610P 2010-08-20 2010-08-20

Publications (1)

Publication Number Publication Date
CL2012003274A1 true CL2012003274A1 (es) 2013-05-24

Family

ID=44462072

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012003274A CL2012003274A1 (es) 2010-05-27 2012-11-23 Compuestos derivados de espiro[biciclo[2.2.1]heptano-2,1-(ciclobutano o ciclopentano) y espiro- ([biciclo]oct[5]eno o biciclo[2.2.2]octano)-2,1-ciclopentano, moduladores de receptores nicotinicos; composicion farmaceutica; utiles en el tratamiento de enfermedades o condicion ibs-d, oab, adiccion a la nicotina, depresion, entre otros.

Country Status (23)

Country Link
US (6) US8809397B2 (es)
EP (1) EP2576496B1 (es)
JP (2) JP5893610B2 (es)
KR (1) KR101856046B1 (es)
CN (2) CN104557568B (es)
AU (1) AU2011258553B2 (es)
BR (1) BR112012030004A2 (es)
CA (1) CA2799203C (es)
CL (1) CL2012003274A1 (es)
CO (1) CO6680603A2 (es)
ES (1) ES2623373T3 (es)
IL (2) IL223060A (es)
MX (1) MX337106B (es)
NZ (1) NZ603966A (es)
PE (1) PE20130775A1 (es)
PH (1) PH12012502300A1 (es)
PL (1) PL2576496T3 (es)
RU (2) RU2582339C2 (es)
SG (1) SG185643A1 (es)
TW (1) TW201200129A (es)
UY (1) UY33409A (es)
WO (2) WO2011149859A1 (es)
ZA (1) ZA201208836B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX337106B (es) * 2010-05-27 2016-02-12 Targacept Inc Antagonistas no competitivos de receptores nicotinicos.
BR112014010719A2 (pt) * 2011-11-03 2017-05-02 Targacept Inc moduladores não competitivos de receptor nicotínico
US8901177B2 (en) * 2012-03-23 2014-12-02 Targacept, Inc. Method of treating bladder disorders
US11840495B2 (en) 2020-12-23 2023-12-12 The Broad Institute, Inc. Compositions and methods related to di-substituted bicyclo[2.2.1] heptanamine-containing compounds

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2931805A (en) * 1958-11-10 1960-04-05 Smith Kline French Lab Spiro [bicyclo [2. 2. 1] heptane-2, 2'-alkylenimines]
US3290215A (en) * 1963-10-29 1966-12-06 Du Pont Use of methanoindanamines as antiviral agents
US3317387A (en) * 1964-05-25 1967-05-02 Du Pont Method of reducing the severity of influenza virus infections
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
US5493026A (en) 1993-10-25 1996-02-20 Organix, Inc. Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
JP2802486B2 (ja) 1995-11-30 1998-09-24 花王株式会社 トリシクロカルボン酸エステルおよびその製造法
US5726189A (en) 1996-05-03 1998-03-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes
CN2284883Y (zh) 1996-07-12 1998-06-24 陈智 纯滚活齿传动
ATE301459T1 (de) * 1996-09-18 2005-08-15 Applied Genetics Inc Dermatics Norbornen- und norbornandiolen zur behandlung von pigmentierungsstörungen, neurodegenerativen erkrankungen oder proliferativen hauterkrankungen
ZA9711092B (en) 1996-12-11 1999-07-22 Smithkline Beecham Corp Novel compounds.
US6310043B1 (en) 1998-08-07 2001-10-30 Governors Of The University Of Alberta Treatment of bacterial infections
GB9821503D0 (en) 1998-10-02 1998-11-25 Novartis Ag Organic compounds
PT1634498E (pt) 1998-12-16 2008-10-28 Univ South Florida Formulação de exo-s-mecamilamina
TW200306189A (en) * 2002-03-21 2003-11-16 Merz Pharma Gmbh & Co Kgaa Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
US7417049B2 (en) * 2002-04-18 2008-08-26 Astrazeneca Ab Furyl compounds
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7825147B2 (en) * 2003-08-29 2010-11-02 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-IV
US20050228023A1 (en) 2003-12-19 2005-10-13 Sri International Agonist and antagonist ligands of the nociceptin receptor
BRPI0417927A (pt) 2003-12-22 2007-04-17 Astrazeneca Ab composto, métodos para o tramento ou a profilaxia de uma doença ou condição, e de distúrbios, e para a indução da cessação do hábito de fumar, composição farmacêutica, e, uso de um composto
JP2008510711A (ja) 2004-08-20 2008-04-10 ターガセプト，インコーポレイテッド 嗜癖治療におけるｎ−アリールジアザスピラ環状化合物の使用
AR054816A1 (es) * 2005-07-13 2007-07-18 Banyu Pharma Co Ltd Derivados de n-dihidroxialquil 2-oxo- imidazol sustituidos
TW200845977A (en) * 2007-03-30 2008-12-01 Targacept Inc Sub-type selective azabicycloalkane derivatives
WO2009039181A2 (en) 2007-09-17 2009-03-26 State Of Oregon Acting By & Through The State Board Of Higher Education On Behalf Of Or. State Univ. Sulfonamide-based organocatalysts and method for their use
JP2011513421A (ja) * 2008-03-05 2011-04-28 ターガセプト，インコーポレイテッド サブタイプ選択的なジアザビシクロアルカンのアミド
MX337106B (es) * 2010-05-27 2016-02-12 Targacept Inc Antagonistas no competitivos de receptores nicotinicos.
WO2013026852A2 (en) * 2011-08-22 2013-02-28 The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Derivatives of mecamylamine

Also Published As

Publication number Publication date
CN104557568A (zh) 2015-04-29
PL2576496T3 (pl) 2017-08-31
US20190254991A1 (en) 2019-08-22
MX2012013618A (es) 2013-02-01
US20140315877A1 (en) 2014-10-23
US10716770B2 (en) 2020-07-21
AU2011258553A1 (en) 2013-01-10
CA2799203C (en) 2018-05-08
IL241743A0 (en) 2015-11-30
TW201200129A (en) 2012-01-01
JP2016172717A (ja) 2016-09-29
JP5893610B2 (ja) 2016-03-23
CN102918021B (zh) 2015-02-11
WO2011149862A1 (en) 2011-12-01
RU2016111390A (ru) 2017-10-04
PH12012502300A1 (en) 2013-02-04
SG185643A1 (en) 2012-12-28
US20170071878A1 (en) 2017-03-16
ZA201208836B (en) 2013-07-31
AU2011258553B2 (en) 2014-08-14
US8809397B2 (en) 2014-08-19
RU2582339C2 (ru) 2016-04-27
CO6680603A2 (es) 2013-05-31
BR112012030004A2 (pt) 2016-08-02
CA2799203A1 (en) 2011-12-01
US10258582B2 (en) 2019-04-16
KR101856046B1 (ko) 2018-06-25
US9532974B2 (en) 2017-01-03
MX337106B (es) 2016-02-12
JP2013528178A (ja) 2013-07-08
EP2576496B1 (en) 2017-03-08
IL223060A0 (en) 2013-02-03
EP2576496A1 (en) 2013-04-10
CN104557568B (zh) 2017-04-12
IL223060A (en) 2015-10-29
ES2623373T3 (es) 2017-07-11
CN102918021A (zh) 2013-02-06
WO2011149859A1 (en) 2011-12-01
KR20130075748A (ko) 2013-07-05
US20160008323A1 (en) 2016-01-14
PE20130775A1 (es) 2013-07-21
US20180271806A1 (en) 2018-09-27
UY33409A (es) 2013-01-03
NZ603966A (en) 2015-03-27
RU2012157224A (ru) 2014-07-10
US20130203860A1 (en) 2013-08-08

Similar Documents

Publication Publication Date Title
MX349754B (es) Metodo para la administracion de 4-((1r,3s)-6-cloro-3-fenil-indan- 1-il)-1,2,2-trimetil-piperazina y de sus sales en el tratamiento de esquinozofrenia.
CL2008002864A1 (es) Compuestos derivados de 2-amino-quinolina, antagonistas del receptor de serotonina 5-ht 5a; procedimiento de preparacion;composicion farmaceutica; y uso de los compuestos en la prevencion o el tratamiento de depresion,trastornos de ansiedad,esquizofrenia,trastornos de panico,trastornos de memoria,demencia,entre otros.
CL2013001677A1 (es) Compuestos derivados de azabiciclo[3.2.1]octano; agonista del receptor x fernesoide (fxr); proceso para preparar los compuestos; compuesto intermediario; composicion farmaceutica y combinacion farmaceutica que comporenden un compuesto; y uso de los compuestos en la preparacion de medicamentos para el tratamiento de dislipidemia.
CL2008003507A1 (es) Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.
UA107334C2 (ru) Производные аминоэфиров алкалоидов и их лекарственные композиции
EA201791239A8 (ru) ТЕТРАГИДРОПИРИДО[3,4-b]ИНДОЛОВЫЕ МОДУЛЯТОРЫ ЭСТРОГЕНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ
NI201500106A (es) Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno.
EA201100161A1 (ru) Производные хинуклидина карбоната и их медицинские композиции
CY1108794T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου
CL2009000724A1 (es) Compuestos derivados de 1,2,3,4-tetrahidro-pirido[3,4-b]indol, moduladores del receptor de histamina, serotonina y dopamina; composicion farmaceutica; kit farmaceutico; y uso para tratar un trastorno cognitivo, psicotico, mediado por neurotransmisores y/o neurologico.
ECSP11011258A (es) Pirimidinas fusionadas
CL2008001946A1 (es) Compuestos derivados de imidazol, antagonistas de receptores ccr2, ccr3, ccr5; procedimiento de preparacion; y uso en el tratamiento de enfermedades vasculares perifericas.
PE20150671A1 (es) Antagonistas del receptor de 5-ht3
MX2011013437A (es) Antagonista y agonistas inversos de histamina h3 y metodos para el uso de los mismos.
WO2014008351A3 (en) Andrographis paniculata compositions and methods for treatment of addictions
CL2012003274A1 (es) Compuestos derivados de espiro[biciclo[2.2.1]heptano-2,1-(ciclobutano o ciclopentano) y espiro- ([biciclo]oct[5]eno o biciclo[2.2.2]octano)-2,1-ciclopentano, moduladores de receptores nicotinicos; composicion farmaceutica; utiles en el tratamiento de enfermedades o condicion ibs-d, oab, adiccion a la nicotina, depresion, entre otros.
DE602007012313D1 (de) Als a2b-adenosinrezeptorantagonisten geeignete 5-phenyl-6-pyridin-4-yl-1,3-dihydro-2h-imidazoä4,5-büpyridin-2-onderivate
MX370898B (es) Agente terapéutico y/o preventivo que comprende un derivado de 1-indansulfamida para el dolor.
MD4538B1 (ro) 1-Piperazino-3-fenil-indani deuteraţi pentru tratamentul schizofreniei
BRPI0807867A2 (pt) Derivado de indol ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um derivado de (indol-3-il) heterociclo, e, método de tratamento de dor
CY1118132T1 (el) ΣΤΕΡΕΕΣ ΜΟΡΦΕΣ ΤΗΣ ΥΔΡΟΧΛΩΡΙΚΗΣ (1R,4R)-6'-ΦΘΟΡΟ-Ν,Ν-ΔΙΜΕΘΥΛ-4-ΦΑΙΝΥΛ-4',9'-ΔΙΥΔΡΟ-3´H-ΣΠΕΙΡΟ-[ΚΥΚΛΟΕΞΑΝΟ-1,1'-ΠΥΡΑΝΟ[3,4,b]ΙΝΔΟΛ]-4-ΑΜΙΝΗΣ
CL2007001795A1 (es) Compuestos derivados de 4-oxo-1,2,8-triaza-espiro[4.5] decano, que actuan como inhibidores del canal de potasio kv1.5; composicion farmaceutica que los comprende; y uso de los compuestos en la prepararcion de medicamentos para tratar o prevenir arritmias cardiacas
CO6300937A2 (es) Derivados de 3-carboxipropil-aminotetralina y compuestos relacionados como antagonistas de receptores opioides mu
AR084882A1 (es) Compuesto de 1-azabiciclo[2.2.2]octano y usos para el tratamiento de esquizofrenia
EA201401268A1 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ (1r,4r)-6'-ФТОР-N,N-ДИМЕТИЛ-4-ФЕНИЛ-4',9'-ДИГИДРО-3'H-СПИРО[ЦИКЛОГЕКСАН-1,1'-ПИРАНО[3,4,b]ИНДОЛ]-4-АМИН И ГАБАПЕНТИНОИД